COVID-19 in rheumatic diseases in Italy: First results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)

Carlo Alberto Scirè, Greta Carrara, Anna Zanetti, Gianpiero Landolfi, Cecilia Chighizola, Alessia Alunno, Laura Andreoli, Roberto Caporali, Roberto Gerli, Gian Domenico Sebastiani, Guido Valesini, Luigi Sinigaglia

Research output: Contribution to journalArticlepeer-review


Background Italy was one of the first countries significantly affected by the coronavirus disease 2019 (COVID-19) epidemic. The Italian Society for Rheumatology promptly launched a retrospective and anonymised data collection to monitor COVID-19 in patients with rheumatic and musculoskeletal diseases (RMDs), the CONTROL-19 surveillance database, which is part of the COVID-19 Global Rheumatology Alliance. Methods CONTROL-19 includes patients with RMDs and proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) updated until May 3rd 2020. In this analysis, only molecular diagnoses were included. The data collection covered demographic data, medical history (general and RMD-related), treatments and COVID-19 related features, treatments, and outcome. In this paper, we report the first descriptive data from the CONTROL-19 registry. Results The population of the first 232 patients (36% males) consisted mainly of elderly patients (mean age 62.2 years), who used corticosteroids (51.7%), and suffered from multi-morbidity (median comorbidities 2). Rheumatoid arthritis was the most frequent disease (34.1%), followed by spondyloarthritis (26.3%), connective tissue disease (21.1%) and vasculitis (11.2%). Most cases had an active disease (69.4%). Clinical presentation of COVID-19 was typical, with systemic symptoms (fever and asthenia) and respiratory symptoms. The overall outcome was severe, with high frequencies of hospitalisation (69.8%), respiratory support oxygen (55.7%), non-invasive ventilation (20.9%) or mechanical ventilation (7.5%), and 19% of deaths. Male patients typically manifested a worse prognosis. Immunomodulatory treatments were not significantly associated with an increased risk of intensive care unit admission/mechanical ventilation/death. Conclusion Although the report mainly includes the most severe cases, its temporal and spatial trend supports the validity of the national surveillance system. More complete data are being acquired in order to both test the hypothesis that RMD patients may have a different outcome from that of the general population and determine the safety of immunomodulatory treatments.

Original languageEnglish
Pages (from-to)748-753
Number of pages6
JournalClinical and Experimental Rheumatology
Issue number4
Publication statusPublished - Jul 1 2020


  • COVID-19
  • Health surveys
  • Immunosuppression
  • Rheumatic diseases

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'COVID-19 in rheumatic diseases in Italy: First results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)'. Together they form a unique fingerprint.

Cite this